Play all audios:
Targeted cancer therapy developer LOXO ONCOLOGY (LOXO) is licensing its two lead drugs to the German pharma giant BAYER, the companies announced Tuesday. Under the agreement, Loxo will
receive $400 million upfront from Bayer in exchange for global development and marketing rights to larotrectinib and LOXO-195. Both drugs target a rare genetic flaw known as TRK gene fusion
found across a range of different cancer types. Loxo is also eligible for another $650 million in payments from Bayer triggered by regulatory approvals and certain sales milestones for both
drugs. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY MARKET-MOVING BIOPHARMA ANALYSIS — BY SUBSCRIBING
TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe